Developer docs
API playgroundTry for free, no card

Search company profiles

Vernal Biosciences

Full company profile

uuid00021hw

Namestring
Vernal Biosciences
Legal namestring
Vernal Biosciences Inc.
Websiteurl
vernal.bio
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Vernal Biosciences is a Burlington/Colchester, Vermont-based contract development and manufacturing organization (CDMO) founded in 2021 that specializes in high-purity mRNA and lipid nanoparticle (LNP) production for research, preclinical, and clinical applications. The company serves biotech and pharmaceutical developers of mRNA therapeutics, vaccines, gene editing therapies, and protein replacement treatments, with named engagements including Repair Biotechnologies and Akagera Medicines. Its product portfolio spans catalog research-grade mRNAs (eGFP, mCherry, FLuc, Cre, hEPO, OVA), custom mRNA synthesis, large-scale preclinical production (1 mg to 25 grams), LNP formulation, GMP-grade manufacturing, and integrated analytical services covering Master Cell Bank through mRNA-LNP characterization.

The technical platform rests on three differentiators: a proprietary next-generation mRNA capping technology achieving >98% Cap-1 efficiency with low dsRNA contamination (~0.08%); a Quality-by-Design (QbD) framework implemented through QbDVision software that captures process-experiment data for predictive scale-up; and a flexible LNP formulation capability supporting multiple administration routes. The Colchester facility (23,000 sq ft) houses GMP production suites, three Grade B cGMP cleanrooms, and analytical labs, while a 20,000 sq ft Essex, VT GMP plant is under construction to add multi-suite capacity with sterile fill-finish, positioning Vernal as a one-stop shop from sequence design to clinical supply.

The business model combines two revenue streams: professional-services CDMO contracts (custom synthesis, process development, GMP manufacturing, analytical services) sold via direct enterprise field sales and quote-based pricing, and transactional catalog mRNA product sales through an e-commerce storefront with tiered unit pricing ($305-$7,169 per SKU) and free samples. Vernal monetizes the outsourcing pain point of building in-house mRNA manufacturing infrastructure, generating revenue across the full R&D lifecycle while targeting biotech, pharma, and academic research institutions. The company has raised approximately $41M across seed (2021), a $21M round (June 2022), and a $20M round (June 2023) led by Ampersand Capital Partners, Charles River Labs, Dynamk Capital, and Alloy Therapeutics, and operates with 51-100 employees under new CEO Jim Petrilla appointed October 2024.

Short descriptiontext

Vernal Biosciences is a Vermont-based mRNA CDMO founded in 2021, offering custom synthesis, LNP formulation, GMP manufacturing, and integrated analytical services for biotech and pharma developers of mRNA therapeutics, vaccines, and gene editing applications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBurlington, United States
HQ citystring
Burlington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mRNA contract manufacturing, lipid nanoparticle formulation, GMP mRNA production, CDMO services, analytical testing services
Industry2 codes
PRIMARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
mRNA Contract Manufacturing (CDMO)
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1CDMO Contract Manufacturing Services
TypeProfessional Services
Description

Full-service contract development and manufacturing organization providing end-to-end mRNA and LNP services from custom synthesis through GMP manufacturing, including process development, analytical services, and sterile fill-finish.

vernal.bio
2Catalog mRNA Product Sales
TypeOne Time License
Description

Sale of research-use catalog mRNA products including reporter genes (eGFP, mCherry, FLuc), gene editing (Cre), gene replacement (hEPO), and antigen (OVA) mRNAs in various quantities from 100UG to 5MG.

vernal.bio
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales
Pricing details5 tiers
1eGFP mRNA - Reporter Gene mRNA for research applications
ModelUnit PricingBilling cadencePay-as-you-go
Notes

100UG: $366; 250UG: $733; 500UG: $1,282; 1MG: $1,992; 5MG: $7,169. Concentration and integrity testing assays provided as standard. Optional add-ons include LNP encapsulation, residual protein/endotoxin/DNA/dsRNA testing, and 5' capping efficiency testing.

vernal.bio
2mCherry mRNA - Reporter Gene mRNA for research applications
ModelUnit PricingBilling cadencePay-as-you-go
Notes

100UG: $305; 250UG: $610; 500UG: $1,068; 1MG: $1,673; 5MG: $5,999

vernal.bio
3FLuc mRNA - Firefly Luciferase mRNA for biodistribution studies
ModelUnit PricingBilling cadencePay-as-you-go
Notes

100UG: $305; 250UG: $610; 500UG: $1,068; 1MG: $1,673; 5MG: $5,999

vernal.bio
4OVA mRNA - Antigen mRNA for immunology research
ModelUnit PricingBilling cadencePay-as-you-go
Notes

100UG: $305; 250UG: $610; 500UG: $1,068; 1MG: $1,673; 5MG: $5,999

vernal.bio
5Custom mRNA synthesis services
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Design and manufacturing of high-purity mRNA for any protein target or application, ranging from precision nucleases to gene regulatory proteins.

vernal.bio
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Vernal Biosciences is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end mRNA and lipid nanoparticle (LNP) manufacturing services from research-grade through GMP-grade production. Its portfolio spans ready-to-order catalog mRNA products (eGFP, mCherry, FLuc, Cre, hEPO, OVA), custom mRNA synthesis, GMP mRNA and LNP-mRNA manufacturing, LNP formulation, large-scale production from 1 mg to 25 grams, analytical services, and pre-GMP development for biotech and pharma drug developers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • >98% Cap-1 capping efficiency ensuring high potency and reduced inflammatory responses
+3 more records
Product overview1 text field

Vernal Biosciences is a Contract Development and Manufacturing Organization (CDMO) offering an integrated platform of mRNA and lipid nanoparticle (LNP) manufacturing services. The portfolio consists of Catalog mRNA Products (eGFP, mCherry, FLuc, Cre, hEPO, OVA mRNA) for research use, Custom mRNA Synthesis for bespoke applications, and GMP mRNA and LNP-mRNA Manufacturing for clinical supply. Supporting services include LNP-Formulated mRNA, mRNA and LNP Analytical Services, mRNA and LNP Large-Scale Production, mRNA Sequence Design, and Pre-GMP mRNA and LNP Development. The platform is unified through a Quality-by-Design approach, enabling seamless technology transfer from research-grade through GMP clinical manufacturing.

Product and service7 records
1Catalog mRNA Products
CategoryCatalog mRNA Reagents
Description

Ready-to-use catalog mRNA products for research and preclinical applications, including reporter gene mRNAs (eGFP, mCherry, FLuc), gene editing mRNA (Cre), gene replacement mRNA (hEPO), and antigen mRNA (OVA), incorporating modified nucleoside, Cap-1 structure, optimized codons, and poly(A) tail. Sold in tiered quantities from 100UG to 5MG to academic and industrial researchers.

2Custom mRNA Synthesis
CategoryCustom mRNA Synthesis Services
Description

Bespoke design and manufacturing of high-purity custom mRNA for any protein target or application, including precision nucleases, gene regulatory proteins, epigenetic editors, secreted and intracellular binding proteins, protein replacement, reporter genes, immunomodulatory genes, cell programming, and fusion proteins. Quote-based service for biotech and pharma developers needing tailored mRNA constructs.

3GMP mRNA and LNP-mRNA Manufacturing
CategoryGMP Contract Manufacturing
Description

GMP-compliant manufacturing services for mRNA drug substance and LNP-mRNA drug product, with detailed process characterization, a Quality-by-Design program, and full analytical assay support for clinical supply. Includes sterile fill-finish. Targeted at biotech and pharma clients advancing mRNA drug candidates into clinical trials.

4LNP-Formulated mRNA
CategoryLNP Formulation Services
Description

Scalable lipid nanoparticle (LNP) formulation services for mRNA delivery using various lipid chemistries, including preclinical LNP manufacturing, formulation optimization, and GMP sterile fill-finish for clinical manufacturing. Supports IV, subcutaneous, intramuscular, intraventricular, and intratumoral routes of administration.

5mRNA and LNP Analytical Services
CategoryAnalytical Testing Services
Description

Comprehensive analytical testing services measuring critical quality attributes (CQAs) across mRNA and LNP manufacturing, including Master Cell Bank, plasmid, mRNA, and mRNA-LNP material testing for capping efficiency, poly(A) tail length, dsRNA content, encapsulation efficiency, and lipid composition. Now offered as integrated analytical and QC services for plasmid DNA, mRNA, and LNPs.

6mRNA and LNP Large-Scale Production
CategoryLarge-Scale mRNA Production
Description

High-purity mRNA and LNP large-scale production for preclinical studies, including dose range finding and toxicology studies, with production scales ranging from 1 mg to 25 grams. Supports biotech and pharma clients running IND-enabling preclinical work.

7Pre-GMP mRNA and LNP Development
CategoryPre-GMP Process Development
Description

Pre-GMP development services including process development, GMP-representative manufacturing process, process documentation, quality establishment, and IND submission support. Designed to de-risk and accelerate the transition from preclinical research to GMP clinical manufacturing.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership to democratize access to mRNA technology around the world. REPROCELL is a trusted leader in life sciences research products and services.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

TriLink is the most direct comparable: a specialized mRNA and nucleic acid CDMO offering catalog and custom mRNA, GMP manufacturing, and clean cap analogs. Both companies serve mRNA therapeutic and vaccine developers with research-grade through GMP services.

TypeDirect peer
Description

Aldevron is a leading plasmid DNA, mRNA, and protein CDMO serving gene therapy and mRNA developers. Now owned by Danaher, it provides comparable end-to-end nucleic acid manufacturing from research to GMP scales, competing directly for mRNA and LNP clients.

TypeBroad incumbent
Description

AGC Biologics is a global CDMO offering mRNA, cell therapy, and biologics manufacturing services. Larger and broader than Vernal but with overlapping mRNA CDMO capabilities and a larger customer base in pharma and biotech.

TypeBroad incumbent
Description

Lonza is one of the largest global CDMOs with significant mRNA and LNP manufacturing capacity built out post-COVID. Operates at much greater scale across multiple modalities; competes for the same pharma customers seeking outsourced mRNA production.

TypeBroad incumbent
Description

Catalent is a major pharmaceutical CDMO with biologics, cell therapy, and nucleic acid capabilities including mRNA. Recently acquired by Novo Holdings, it competes with Vernal for outsourced manufacturing relationships with biotech and pharma clients.

6Recipharm (Ettore Biologics)
TypeBroad incumbent
Description

Recipharm is a European-headquartered CDMO with biologics and nucleic acid capabilities. Operates broader service lines than Vernal but overlaps in mRNA-related manufacturing services for biotech and pharma clients.

TypeEmerging player
Description

eTheRNA is a Belgium-based mRNA therapeutics developer and CDMO with proprietary LNP technology. Smaller and more focused on its own pipeline but competes for mRNA CDMO clients in the European market.

TypeBroad incumbent
Description

Thermo Fisher's Patheon business is a top-tier global pharma CDMO offering drug substance, drug product, and biologics services. While not specialized in mRNA, it serves many of the same biotech customers and competes for outsourcing budgets.

TypeBroad incumbent
Description

Samsung Biologics is a large-scale biologics CDMO with expanding mRNA and vaccine manufacturing capabilities. Significantly larger scale and capacity; serves large pharma clients across multiple modalities.

TypeEmerging player
Description

Eurofins Genomics offers custom DNA/RNA synthesis and gene synthesis services with growing mRNA capabilities. Comparable to Vernal's catalog and custom mRNA product lines, particularly for research-grade applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vernal Biosciences

mRNA Contract Manufacturing (CDMO)vernal.bio

Vernal Biosciences is a Vermont-based mRNA CDMO founded in 2021, offering custom synthesis, LNP formulation, GMP manufacturing, and integrated analytical services for biotech and pharma developers of mRNA therapeutics, vaccines, and gene editing applications.

What Vernal Biosciences does

Vernal Biosciences is a Burlington/Colchester, Vermont-based contract development and manufacturing organization (CDMO) founded in 2021 that specializes in high-purity mRNA and lipid nanoparticle (LNP) production for research, preclinical, and clinical applications. The company serves biotech and pharmaceutical developers of mRNA therapeutics, vaccines, gene editing therapies, and protein replacement treatments, with named engagements including Repair Biotechnologies and Akagera Medicines. Its product portfolio spans catalog research-grade mRNAs (eGFP, mCherry, FLuc, Cre, hEPO, OVA), custom mRNA synthesis, large-scale preclinical production (1 mg to 25 grams), LNP formulation, GMP-grade manufacturing, and integrated analytical services covering Master Cell Bank through mRNA-LNP characterization.

The technical platform rests on three differentiators: a proprietary next-generation mRNA capping technology achieving >98% Cap-1 efficiency with low dsRNA contamination (~0.08%); a Quality-by-Design (QbD) framework implemented through QbDVision software that captures process-experiment data for predictive scale-up; and a flexible LNP formulation capability supporting multiple administration routes. The Colchester facility (23,000 sq ft) houses GMP production suites, three Grade B cGMP cleanrooms, and analytical labs, while a 20,000 sq ft Essex, VT GMP plant is under construction to add multi-suite capacity with sterile fill-finish, positioning Vernal as a one-stop shop from sequence design to clinical supply.

The business model combines two revenue streams: professional-services CDMO contracts (custom synthesis, process development, GMP manufacturing, analytical services) sold via direct enterprise field sales and quote-based pricing, and transactional catalog mRNA product sales through an e-commerce storefront with tiered unit pricing ($305-$7,169 per SKU) and free samples. Vernal monetizes the outsourcing pain point of building in-house mRNA manufacturing infrastructure, generating revenue across the full R&D lifecycle while targeting biotech, pharma, and academic research institutions. The company has raised approximately $41M across seed (2021), a $21M round (June 2022), and a $20M round (June 2023) led by Ampersand Capital Partners, Charles River Labs, Dynamk Capital, and Alloy Therapeutics, and operates with 51-100 employees under new CEO Jim Petrilla appointed October 2024.

Vernal Biosciences firmographics

Firmographics
Name
Vernal Biosciences
Legal name
Vernal Biosciences Inc.
Website
https://vernal.bio
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Vernal Biosciences is a Vermont-based mRNA CDMO founded in 2021, offering custom synthesis, LNP formulation, GMP manufacturing, and integrated analytical services for biotech and pharma developers of mRNA therapeutics, vaccines, and gene editing applications.
Ownership category
akta.pro rank

Vernal Biosciences industry classification

Industry
Product category
mRNA Contract Manufacturing (CDMO)
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • MRNA contract manufacturing
  • Lipid nanoparticle formulation
  • GMP mRNA production
  • CDMO services
  • Analytical testing services

Where Vernal Biosciences is headquartered

Location

Headquarters

HQ city
Burlington
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Vernal Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Infrastructure, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. CDMO Contract Manufacturing Services: Full-service contract development and manufacturing organization providing end-to-end mRNA and LNP services from custom synthesis through GMP manufacturing, including process development, analytical services, and sterile fill-finish.
  2. Catalog mRNA Product Sales: Sale of research-use catalog mRNA products including reporter genes (eGFP, mCherry, FLuc), gene editing (Cre), gene replacement (hEPO), and antigen (OVA) mRNAs in various quantities from 100UG to 5MG.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goeGFP mRNA - Reporter Gene mRNA for research applications
Unit PricingPay-as-you-gomCherry mRNA - Reporter Gene mRNA for research applications
Unit PricingPay-as-you-goFLuc mRNA - Firefly Luciferase mRNA for biodistribution studies
Unit PricingPay-as-you-goOVA mRNA - Antigen mRNA for immunology research
OtherMulti-year contractCustom mRNA synthesis services

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Vernal Biosciences product offering

Product offering

Core offering

Vernal Biosciences is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end mRNA and lipid nanoparticle (LNP) manufacturing services from research-grade through GMP-grade production. Its portfolio spans ready-to-order catalog mRNA products (eGFP, mCherry, FLuc, Cre, hEPO, OVA), custom mRNA synthesis, GMP mRNA and LNP-mRNA manufacturing, LNP formulation, large-scale production from 1 mg to 25 grams, analytical services, and pre-GMP development for biotech and pharma drug developers.

Product overview

Vernal Biosciences is a Contract Development and Manufacturing Organization (CDMO) offering an integrated platform of mRNA and lipid nanoparticle (LNP) manufacturing services. The portfolio consists of Catalog mRNA Products (eGFP, mCherry, FLuc, Cre, hEPO, OVA mRNA) for research use, Custom mRNA Synthesis for bespoke applications, and GMP mRNA and LNP-mRNA Manufacturing for clinical supply. Supporting services include LNP-Formulated mRNA, mRNA and LNP Analytical Services, mRNA and LNP Large-Scale Production, mRNA Sequence Design, and Pre-GMP mRNA and LNP Development. The platform is unified through a Quality-by-Design approach, enabling seamless technology transfer from research-grade through GMP clinical manufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

  • Catalog mRNA Products Ready-to-use catalog mRNA products for research and preclinical applications, including reporter gene mRNAs (eGFP, mCherry, FLuc), gene editing mRNA (Cre), gene replacement mRNA (hEPO), and antigen mRNA (OVA), incorporating modified nucleoside, Cap-1 structure, optimized codons, and poly(A) tail. Sold in tiered quantities from 100UG to 5MG to academic and industrial researchers.
  • Custom mRNA Synthesis Bespoke design and manufacturing of high-purity custom mRNA for any protein target or application, including precision nucleases, gene regulatory proteins, epigenetic editors, secreted and intracellular binding proteins, protein replacement, reporter genes, immunomodulatory genes, cell programming, and fusion proteins. Quote-based service for biotech and pharma developers needing tailored mRNA constructs.
  • GMP mRNA and LNP-mRNA Manufacturing GMP-compliant manufacturing services for mRNA drug substance and LNP-mRNA drug product, with detailed process characterization, a Quality-by-Design program, and full analytical assay support for clinical supply. Includes sterile fill-finish. Targeted at biotech and pharma clients advancing mRNA drug candidates into clinical trials.
  • LNP-Formulated mRNA Scalable lipid nanoparticle (LNP) formulation services for mRNA delivery using various lipid chemistries, including preclinical LNP manufacturing, formulation optimization, and GMP sterile fill-finish for clinical manufacturing. Supports IV, subcutaneous, intramuscular, intraventricular, and intratumoral routes of administration.
  • mRNA and LNP Analytical Services Comprehensive analytical testing services measuring critical quality attributes (CQAs) across mRNA and LNP manufacturing, including Master Cell Bank, plasmid, mRNA, and mRNA-LNP material testing for capping efficiency, poly(A) tail length, dsRNA content, encapsulation efficiency, and lipid composition. Now offered as integrated analytical and QC services for plasmid DNA, mRNA, and LNPs.
  • mRNA and LNP Large-Scale Production High-purity mRNA and LNP large-scale production for preclinical studies, including dose range finding and toxicology studies, with production scales ranging from 1 mg to 25 grams. Supports biotech and pharma clients running IND-enabling preclinical work.
  • Pre-GMP mRNA and LNP Development Pre-GMP development services including process development, GMP-representative manufacturing process, process documentation, quality establishment, and IND submission support. Designed to de-risk and accelerate the transition from preclinical research to GMP clinical manufacturing.

Quantifiable outcome

  • >98% Cap-1 capping efficiency ensuring high potency and reduced inflammatory responses
  • +3 more outcomes

Companies that use Vernal Biosciences

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Vernal Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Vernal Biosciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • REPROCELLcoreStrategic or Co-development PartnerPartnership to democratize access to mRNA technology around the world. REPROCELL is a trusted leader in life sciences research products and services.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Vernal Biosciences competitors and assessment

Company assessment

Direct peers

  • TriLink BioTechnologies (Maravai LifeSciences): TriLink is the most direct comparable: a specialized mRNA and nucleic acid CDMO offering catalog and custom mRNA, GMP manufacturing, and clean cap analogs. Both companies serve mRNA therapeutic and vaccine developers with research-grade through GMP services.
  • Aldevron (Danaher): Aldevron is a leading plasmid DNA, mRNA, and protein CDMO serving gene therapy and mRNA developers. Now owned by Danaher, it provides comparable end-to-end nucleic acid manufacturing from research to GMP scales, competing directly for mRNA and LNP clients.

Broad incumbents

  • AGC Biologics: AGC Biologics is a global CDMO offering mRNA, cell therapy, and biologics manufacturing services. Larger and broader than Vernal but with overlapping mRNA CDMO capabilities and a larger customer base in pharma and biotech.
  • Lonza: Lonza is one of the largest global CDMOs with significant mRNA and LNP manufacturing capacity built out post-COVID. Operates at much greater scale across multiple modalities; competes for the same pharma customers seeking outsourced mRNA production.
  • Catalent (Novo Holdings): Catalent is a major pharmaceutical CDMO with biologics, cell therapy, and nucleic acid capabilities including mRNA. Recently acquired by Novo Holdings, it competes with Vernal for outsourced manufacturing relationships with biotech and pharma clients.
  • Recipharm (Ettore Biologics): Recipharm is a European-headquartered CDMO with biologics and nucleic acid capabilities. Operates broader service lines than Vernal but overlaps in mRNA-related manufacturing services for biotech and pharma clients.
  • Patheon (Thermo Fisher Scientific): Thermo Fisher's Patheon business is a top-tier global pharma CDMO offering drug substance, drug product, and biologics services. While not specialized in mRNA, it serves many of the same biotech customers and competes for outsourcing budgets.
  • Samsung Biologics: Samsung Biologics is a large-scale biologics CDMO with expanding mRNA and vaccine manufacturing capabilities. Significantly larger scale and capacity; serves large pharma clients across multiple modalities.

Emerging players

  • eTheRNA immunotherapies: eTheRNA is a Belgium-based mRNA therapeutics developer and CDMO with proprietary LNP technology. Smaller and more focused on its own pipeline but competes for mRNA CDMO clients in the European market.
  • Eurofins Genomics: Eurofins Genomics offers custom DNA/RNA synthesis and gene synthesis services with growing mRNA capabilities. Comparable to Vernal's catalog and custom mRNA product lines, particularly for research-grade applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Vernal Biosciences social profiles

Digital presence

Vernal Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vernal Biosciences leadership team

Management profile

Number of profiles

Profiles4 records

Vernal Biosciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vernal Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vernal Biosciences

What does Vernal Biosciences do?

Vernal Biosciences is a Contract Development and Manufacturing Organization (CDMO) providing end-to-end mRNA and lipid nanoparticle (LNP) manufacturing services from research-grade through GMP-grade production. Its portfolio spans ready-to-order catalog mRNA products (eGFP, mCherry, FLuc, Cre, hEPO, OVA), custom mRNA synthesis, GMP mRNA and LNP-mRNA manufacturing, LNP formulation, large-scale production from 1 mg to 25 grams, analytical services, and pre-GMP development for biotech and pharma drug developers.

Is Vernal Biosciences a public or private company?

Vernal Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vernal Biosciences founded?

Vernal Biosciences was founded in 2021. It employs 1 to 10 people.

Where is Vernal Biosciences based?

Vernal Biosciences is headquartered in Burlington, United States, in the North America region.

How does Vernal Biosciences make money?

Two revenue lines are on record. CDMO Contract Manufacturing Services are the primary driver. The others are catalog mRNA Product Sales.

Who are Vernal Biosciences's main competitors?

Direct peers on record are TriLink BioTechnologies (Maravai LifeSciences) and Aldevron (Danaher). Broad incumbents are AGC Biologics, Lonza, Catalent (Novo Holdings), Recipharm (Ettore Biologics), Patheon (Thermo Fisher Scientific) and Samsung Biologics. Emerging players are eTheRNA immunotherapies and Eurofins Genomics.

Does Vernal Biosciences have an API?

No public API is recorded for Vernal Biosciences.

What industry is Vernal Biosciences in?

Vernal Biosciences's product category is mRNA Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO, with a secondary code of HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmiWeb.comLipid Nanoparticles CDMO Market to Witness Double-Digit Growth by 2027The global lipid nanoparticle CDMO market is projected to see double-digit growth by 2027, driven by mRNA vaccine demand and a pipeline of over 2,000 LNP-related drugs. Private equity investments, such as Vernal Biosciences' $20 million round, and strategic partnerships are accelerating capacity expansion. The market is expected to maintain momentum as applications expand across vaccines, oncology, and gene therapies.VernalAdvancing mRNA TherapeuticsAkagera Medicines partnered with Vernal Biosciences to secure high-purity mRNA, aiming to enhance vaccine efficacy and accelerate development for infectious diseases in cost-sensitive regions. This collaboration addresses previous supply chain issues where competitor materials contained up to 20% impurities, which had hindered Akagera's research progress.Venture Capital Access OnlineVermont-based CDMO, Vernal Biosciences Announces an Additional $20MM in Funding to Expand GMP mRNA and LNP ManufacturingVermont-based CDMO Vernal Biosciences completed a $20 million funding round led by Ampersand Capital Partners and Charles River Labs to finance its first GMP manufacturing facility. The company intends to use the capital to expand its mRNA and lipid nanoparticle capabilities, supporting both research and commercial-scale production.VC News DailyVernal Biosciences Pulls In $20MVernal Biosciences, a Burlington, Vermont-based mRNA and LNP Contract Development and Manufacturing Organization, has completed a $20 million funding round led by Ampersand Capital Partners and Charles River Labs, with participation from Dynamk Capital and the Vermont Center for Emerging Technologies. Founded in 2021, the company focuses on manufacturing and formulating mRNA and LNP-mRNA products under Good Manufacturing Practices for research, preclinical, and clinical development needs. The funding will support the company's mission to accelerate and democratize access to mRNA platform technologies.SecSEC FORM DVernal Biosciences, Inc. filed a Form D with the SEC for an exempt offering of securities under Rule 506(b). The filing indicates that the company has sold $40,998,390 worth of equity securities to 10 investors as of May 10, 2022. This regulatory submission serves as a formal notice of the private placement offering.FinSMEsVernal Biosciences Raises $21M in FundingVernal Biosciences closed a $21 million financing round led by Ampersand Capital Partners and Dynamk Capital, with new investor Charles River Laboratories. The funds will support growth and construction of full GMP capabilities scheduled to become operational in late 2023.PR NewswireVernal Biosciences Raises $21 Million to Accelerate mRNA Manufacturing GrowthVernal Biosciences completed a $21 million financing round led by Ampersand Capital Partners and Dynamk Capital to fully integrate its mRNA manufacturing solutions. The funds will support the construction of full GMP capabilities scheduled to become operational in late 2023, expanding the company's services from sequence design to clinical-scale manufacturing. This investment aims to address market demand for integrated providers of high-purity mRNA products and services.Burlington Free PressThis Colchester startup is making mRNA, the basis for more than just vaccinesVernal Biosciences, a Colchester startup, produces mRNA for pharmaceutical companies, including those developing vaccines like those from Moderna and Pfizer. The company plans to scale up manufacturing in Vermont, potentially building a facility costing hundreds of millions of dollars. It has one vaccine client and is working with major investors.Current NewsVernal Biosciences closes seed funding round for its mRNA manufacturingVernal Biosciences closed a seed funding round led by Alloy Therapeutics, with participation from the Vermont Center for Emerging Technologies and individual angel investors. The company plans to use the proceeds to scale its technical development and commercial operations in Vermont, specifically adding GMP clinical manufacturing capabilities for mRNA production. This expansion aims to support clients across research and preclinical stages by providing high-purity mRNA manufacturing services.AlloytxVernal Biosciences Launches to Democratize Access to High Quality mRNA ManufacturingVernal Biosciences launched with seed financing led by Alloy Therapeutics to provide high-purity mRNA manufacturing services for research and clinical-stage programs. The company, founded by mRNA veteran Christian Cobaugh, aims to democratize access to mRNA manufacturing technologies that have historically been concentrated within select therapeutics companies. Proceeds will scale Vernal's technical development and add GMP clinical manufacturing capabilities while Alloy's CEO joins Vernal's board as part of the investment.